NeuroMetrix Reports High Level Of Media Coverage For Quell In First Quarter
BOSTON--(BUSINESS WIRE)--NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company’s innovative Quell® Wearable Pain Relief Technology™. Highlights include:
•Newsweek – This FDA-approved wearable says it relieves chronic pain without any drugs
•Boston Globe – FDA approves upgrade to Quell, a dongle that zaps away pain
•Newsweek – This FDA-approved wearable says it relieves chronic pain without any drugs
•Boston Globe – FDA approves upgrade to Quell, a dongle that zaps away pain